Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
Fowler NH, Davis RE, Rawal S et al (2014) Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15:1311–1318CrossRef
2.
Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944–2952CrossRef
3.
Gogia A, Raina V, Kumar L et al (2017) Follicular lymphoma: an Institutional analysis. Asian Pac J Cancer Prev. 18:681–685PubMedPubMedCentral
4.
Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label multicentre, randomized, phase 3 noninferiority trial. Lancet 381:1203–1210CrossRef
5.
Mondello P, Steiner N, Willenbacher W et al (2018) Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicentre, retrospective study. Oncologist 23:454–460CrossRef
6.
Morschhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 379:934–947CrossRef
7.
Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu MW (2010) Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 16(7):1PubMed
Metadata
Title
Safety and Efficacy of Bendamustine-Rituximab in Treatment Naïve Symptomatic Follicular Lymphoma: An Institutional Analysis
Authors
Ajay Gogia
Sudhir Kumar
Lalit Kumar
Atul Sharma
Soumya Mallick
Publication date
01-01-2021
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2021
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01294-9

Other articles of this Issue 1/2021

Indian Journal of Hematology and Blood Transfusion 1/2021 Go to the issue

Correspondence

COVID-19 in Adult Patients with Hematological Disease: Analysis of Clinical Characteristics and Outcomes

Original Article

Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study

Correspondence

Successful Treatment of Acquired Hemophilia A with Bortezomib Plus Low Dose Rituximab in a Patient with Renal Failure and Severe Pneumonia

Original Article

The Association of Pre-diagnostic Inflammatory Markers and Adipokines and the Risk of Non-Hodgkin Lymphoma Development in Egypt

Original Article

Inherited Bleeding Disorders in Pediatric Patients; experience of the national referral center in Iraq

Original Article

Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits